Waldencast plc has signed a definitive agreement to sell dermatology skincare brand Obagi Medical to UK investment firm Bridgepoint for up to $460 million. The deal marks a strategic shift for Waldencast, allowing it to strengthen its balance sheet and accelerate global expansion of Milk Makeup. For overseas buyers and distributors, this signals a renewed focus on professional-channel skincare and potential new partnership opportunities under Bridgepoint’s ownership.
Deal details and strategic rationale
The transaction, valued at up to $460 million, is a key step in Waldencast’s strategy to focus on Milk Makeup’s global growth. Waldencast founders Michel Brousset and Hind Sebti, along with part of the management team, will leave Waldencast to lead Obagi Medical in collaboration with Bridgepoint. Waldencast Chairman Felipe Dutra stated that the sale strengthens the company’s balance sheet and sharpens its strategic focus on Milk Makeup, which has high global growth potential.
Bridgepoint’s vision for Obagi Medical
Fabrice Turk, Head of Healthcare and Partner at Bridgepoint, highlighted Obagi Medical’s strong scientific foundation, deep physician relationships, and pioneering position in physician-dispensed skincare. He noted that physician-dispensed skincare is one of the fastest-growing segments in dermatology and aesthetic medicine. The acquisition builds on Bridgepoint’s track record in the dermatology, aesthetic medicine, and skincare ecosystem, including its investment in Laboratoires Vivacy, and opens further partnership opportunities.
Obagi Medical’s market position and recent developments
Founded nearly 40 years ago, Obagi Medical is a pioneer in medical-grade skincare, offering both prescription and over-the-counter products. Its portfolio addresses key consumer concerns in the professional channel, including early aging, photoaging, hyperpigmentation, acne, and sun damage. The brand operates through dermatologists, aesthetic practitioners, and other medical professionals in North America, Europe, Asia, and the Middle East. Since its acquisition by Waldencast in 2022, Obagi has expanded its direct-to-physician business, built a strong online presence, and driven international growth, leading to significant profitability expansion. Last year, it acquired Novaestiq, and in Q1 2026 launched the FDA-approved Obagi Saypha MagIQ dermal filler line, positioning itself as a comprehensive beauty and aesthetics megabrand.
What buyers should watch
For overseas importers, distributors, and clinic buyers, this sale signals potential changes in product availability, pricing, and channel strategy under Bridgepoint’s ownership. The focus on physician-dispensed skincare and the recent launch of FDA-approved dermal fillers may expand Obagi’s product range and market reach. Buyers should monitor Bridgepoint’s plans for international distribution and partnership opportunities, especially in regions where Obagi already has a presence, such as Asia and the Middle East.
Sourcing context
Bridgepoint’s investment in Obagi Medical, alongside its existing stake in Laboratoires Vivacy, strengthens its position in the dermatology and aesthetic medicine supply chain. This could lead to synergies in sourcing, manufacturing, and distribution of injectables and skincare products. Buyers may benefit from a more integrated supply chain and potentially new product bundles or exclusive distribution agreements in the future.
Source: Read the original report | Published: June 02, 2026